References
Schjøtt J, Reppe LA, Roland PD,Westergren T (2012) A question-answer pair (QAP) database integrated with websites to answer complex questions submitted to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive study. BMJ Open 2:e000642
Schjøtt J. (2017) Benefits of a national network of drug information centres: RELIS. Eur J Clin Pharmacol. 73(1):125–126.
Harpaz R, DuMouchel W, Shan NH, Mdigan D, Ryan P, Friedman C (2012) Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther 91(6):1010–1021
Ventola CL (2018) Big data and pharmacovigilance: data mining for adverse drug events and interactions. P T 43(6):340–351
Anon (2016) Quetiapine: misuse and abuse. Prescrire Int 25(169):68
Chiappini S, Schifano F (2018) Is there a potential of misuse for quetiapine?: literature review and analysis of the European Medicines Agency/European Medicines Agency adverse drug reactions’ database. J Clin Psychopharmacol 38(1):72–79
Lee J, Pilgrim J, Gerostamoulos D, Robinson J, Wong A (2018) Increasing rates of quetiapine overdose, misuse, and mortality in Victoria, Australia. Drug Alcohol Depend 187:95–99
Evoy KE, Morrison MD, Saklad SR (2017) Abuse and misuse of pregabalin and gabapentin. Drugs 77(4):403–426
Schifano F (2014) Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 28(6):491–496
Bonnet U, Scherbaum N (2017) How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 27(12):1185–1215
Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M (2019) Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.13892
Böhm R. Primer on disproportionality analysis. Version: 2018-10-16. http://openvigil.sourceforge.net/doc/DPA.pdf. Accessed 10th April 2019
Author information
Authors and Affiliations
Contributions
The manuscript was drafted by the idea of Jan Schjøtt, who is also responsible for the statistics. Charlotte L. Stokes has contributed in writing, reference search, and submission.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Stokes, C.L., Schjøtt, J. Disproportionality analysis for identification of drug safety signals in a database shared by the Norwegian network of drug information centres (RELIS). Eur J Clin Pharmacol 75, 1469–1470 (2019). https://doi.org/10.1007/s00228-019-02717-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-019-02717-x